AN2 Therapeutics, Inc. (ANTX)
4.60
-0.05
(-1.08%)
USD |
NASDAQ |
May 07, 14:41
AN2 Therapeutics SG&A Expense (TTM) : 13.34M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Relmada Therapeutics, Inc. | 32.22M |
| ACADIA Pharmaceuticals, Inc. | 548.89M |
| Alnylam Pharmaceuticals, Inc. | 1.293B |
| Savara, Inc. | 42.06M |
| BioMarin Pharmaceutical, Inc. | 946.91M |